1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. Raf
  4. BRaf Isoform

BRaf

 

BRaf Related Products (53):

Cat. No. Product Name Effect Purity
  • HY-10201
    Sorafenib
    Inhibitor 99.92%
    Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively.
  • HY-12057
    Vemurafenib
    Inhibitor 99.83%
    Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively.
  • HY-14660
    Dabrafenib
    Inhibitor 99.91%
    Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively.
  • HY-10331
    Regorafenib
    Inhibitor 99.65%
    Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
  • HY-10320
    Doramapimod
    Inhibitor 99.98%
    Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM.
  • HY-77113
    B-Raf IN 11
    Inhibitor
    B-Raf IN 11 (ZINC72115182) is a selective B-RafV600E inhibitor (IC50=76 nM), shows selectivity for B-RafV600E over B-RafWT with selectivity of 3.1-fold.
  • HY-147405
    Tinlorafenib
    Inhibitor
    Tinlorafenib (PF-07284890) (compound 10) is an orally active BRAF kinase inhibitor, with IC50s of 4.25 and 2.7 nM for BRAFV600E/V600K respectively.
  • HY-10331B
    Regorafenib mesylate
    Inhibitor
    Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
  • HY-10201A
    Sorafenib Tosylate
    Inhibitor 99.75%
    Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively.
  • HY-51424
    PLX-4720
    Inhibitor 99.91%
    PLX-4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
  • HY-109080
    Belvarafenib
    Inhibitor 98.05%
    Belvarafenib (HM95573) is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
  • HY-11004
    AZ 628
    Inhibitor 99.86%
    AZ 628 is a pan-Raf kinase inhibitor with IC50s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.
  • HY-12558
    LY3009120
    Inhibitor 98.97%
    LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAFV600E, BRAFWT and CRAFWT with IC50s of 5.8, 9.1 and 15 nM, respectively.
  • HY-18652
    Avutometinib
    Inhibitor 98.99%
    Avutometinib (Ro 5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAFV600E, CRAF, MEK, and BRAF (IC50: 8.2, 56, 160 nM, and 190 nM, respectively).
  • HY-50864
    GDC-0879
    Inhibitor 99.57%
    GDC-0879 is a potent and selective B-Raf inhibitor with an IC50 of 0.13 nM.
  • HY-10966
    SB-590885
    Inhibitor 99.56%
    SB-590885 is a potent B-Raf inhibitor with Ki of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.
  • HY-14660A
    Dabrafenib Mesylate
    Inhibitor 99.95%
    Dabrafenib (Mesylate) is a novel, potent, and selective Raf kinase inhibitor, and inhibits the kinase activity of B-RafV600Eand c-Raf with IC50 values of 0.6 and 5.0 nM, respectively.
  • HY-112089
    LXH254
    Inhibitor 99.95%
    LXH254 is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively.
  • HY-18957
    Lifirafenib
    Inhibitor 98.73%
    Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
  • HY-100510
    RAF709
    Inhibitor 98.87%
    RAF709 is a potent, selective, and efficacious RAF inhibitor with IC50s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively.